Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: J05AR19

Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris(emtricitabine;rilpivirine hydrochloride;tenofovir alafenamide fumarate)

HIV Infections

Marketing Authorisation Holder: Viatris Limited

EMA Authorisation: 19/08/2025

INN: emtricitabine;rilpivirine;tenofovir alafenamide

Indication

Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus-1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load ≤ 100 000 HIV 1 RNA copies/mL (see sections 4.2, 4.4 and 5.1). 

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.